Vancouver, Canada – July 17, 2025 – Augurex Life Sciences today announced it will be exhibiting and presenting new data at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), taking place July 27–31 in Chicago, IL.
As one of the world’s leading events for laboratory medicine, ADLM brings together leaders in clinical diagnostics, laboratory innovation, and healthcare transformation.
Augurex will be presenting new data during the poster session:
Poster B-115 – Wednesday, July 30 | 1:30–2:30 PM
Development of Anti-14-3-3η Multiplex Laboratory Developed Test (LDT) to Aid in the Diagnosis of Axial Spondyloarthritis (axSpA)
Presenter: Anthony Marotta, PhD
Augurex will also be showcasing its two flagship diagnostic solutions at Booth #2062:
- JOINTstat® | 14-3-3eta: An ELISA-based biomarker test that supports the early diagnosis, prognosis and ongoing monitoring of rheumatoid arthritis (RA).
- SPINEstat® | Anti-14-3-3eta Multiplex: A first-in-class test for the early and accurate diagnosis of axial spondyloarthritis (axSpA), helping clinicians distinguish inflammatory disease from mechanical back pain.
Diagnostic delays remain a significant challenge in autoimmune disease, and Augurex is advancing precision laboratory tools to deliver earlier, more objective results that improve the continuum of care.
Visit Booth #2062 or reach out to schedule a meeting to learn how JOINTstat® and SPINEstat® are helping laboratories enhance autoimmune testing accuracy and clinical value.
For more information, visit: ADLM 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com